Elequin Capital LP Cerevel Therapeutics Holdings, Inc. Transaction History

Elequin Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$20.27 - $42.44 $121 - $254	-6 Reduced 37.5%	10 $0
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $8,002 - $12,604	-395 Reduced 96.11%	16 $0
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $9,822 - $14,541	411 New	411 $13,000
Q4 2022 Feb 09, 2023	BUY	$25.35 - $31.96 $23,372 - $29,467	922 New	922 $29,000

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Elequin Capital LP, based on Form 13F filings with the SEC.

Stay updated on Elequin Capital LP with notifications on news.